Stuttgart
12.12.25 | 08:08
0,451 Euro
0,00 % 0,000
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mi | Egetis Therapeutics AB: Egetis and Er-Kim Expand Partnership to Broaden Access to Emcitate Across Central, Eastern, and Southeastern Europe | 52 | GlobeNewswire (Europe) | Stockholm, Sweden, December 10, 2025. Egetis Therapeutics AB (publ) ("Egetis" or the "Company") (NASDAQ Stockholm: EGTX), today announced that the Company, through its wholly-owned subsidiary Rare Thyroid... ► Artikel lesen | |
| 25.11. | Egetis-Aktie unter Druck: Positive Studiendaten können Kursverlust nach Q3-Zahlen nicht verhindern | 2 | Investing.com Deutsch | ||
| 25.11. | Egetis Therapeutics AB: Interim report Q3 2025 | 99 | GlobeNewswire (Europe) | Egetis to commence a rolling NDA submission in December as granted by the FDA for Emcitate® (tiratricol)· Egetis received FDA Breakthrough Therapy Designation for Emcitate® (tiratricol) for... ► Artikel lesen | |
| 14.11. | Egetis Therapeutics AB: Egetis announces positive results from the ReTRIACt study of Emcitate (tiratricol) in MCT8 deficiency | 79 | GlobeNewswire (Europe) | Positive topline results demonstrate a statistically significant (p=0.034) difference in the rate of change in serum T3 in patients randomized to withdrawal (placebo) vs. in patients continuing therapy... ► Artikel lesen | |
| 23.10. | Egetis Therapeutics AB: Egetis granted a rolling NDA review by FDA for Emcitate (tiratricol) based on currently available clinical data | 152 | GlobeNewswire (Europe) | The outcomes of a successful pre-NDA meeting with the FDA are:
As agreed with the FDA, the rolling NDA submission will commence in December 2025, targeting a complete NDA submission in early 2026 and... ► Artikel lesen | |
| EGETIS THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 02.10. | Egetis Therapeutics AB: Egetis Therapeutics intends to carry out a directed share issue of up to 10 percent of outstanding ordinary shares | 141 | GlobeNewswire (Europe) | NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, HONG KONG, ISRAEL, JAPAN, NEW ZEALAND, SOUTH AFRICA... ► Artikel lesen | |
| 21.08. | Egetis Therapeutics: Aktie steigt nach Q2-Zahlen trotz verfehlter Umsatzprognose | 2 | Investing.com Deutsch | ||
| 21.08. | Egetis Therapeutics AB: Interim report Q2 2025 | 183 | GlobeNewswire (Europe) | Egetis reports progress towards US NDA submission for tiratricol· FDA awarded tiratricol Breakthrough Therapy Designation (BTD) in July 2025, based on the Agency's review of Egetis' analysis... ► Artikel lesen | |
| 18.08. | Egetis Therapeutics AB: Egetis reports progress towards US NDA submission for tiratricol | 453 | GlobeNewswire (Europe) | FDA awarded tiratricol Breakthrough Therapy Designation (BTD) in July 2025, based on the Agency's review of Egetis' analysis of the survival data set from the international real-world cohort study by... ► Artikel lesen | |
| 15.07. | Egetis Therapeutics AB: Egetis receives FDA Breakthrough Therapy Designation for tiratricol for MCT8 deficiency | 293 | GlobeNewswire (Europe) | Stockholm, Sweden, July 15, 2025. Egetis Therapeutics AB (publ) ("Egetis" or the "Company") (NASDAQ Stockholm: EGTX), today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough... ► Artikel lesen | |
| 05.05. | Egetis Therapeutics AB: Egetis Confirms Launch of Emcitate in Germany | 453 | GlobeNewswire (Europe) | For investors and media only
Stockholm, Sweden, May 5, 2025. Egetis Therapeutics AB (publ) ("Egetis" or the "Company") (NASDAQ Stockholm: EGTX), a pharmaceutical company dedicated to developing therapies... ► Artikel lesen | |
| 30.04. | Egetis Therapeutics AB: Interim report Q1 2025 | 168 | GlobeNewswire (Europe) | Egetis plans to launch Emcitate® in the first country, Germany, on May 1, 2025The European Commission approved Emcitate® (tiratricol) as the first and only treatment for patients with MCT8 deficiency.In... ► Artikel lesen | |
| 26.02. | Egetis Therapeutics AB: Year-End Report January-December 2024 | 348 | GlobeNewswire (Europe) | European Commission has approved Egetis' Emcitate® (tiratricol) as the first and only treatment for patients with MCT8 deficiency· Egetis expects to launch Emcitate in the first country, Germany... ► Artikel lesen | |
| 13.02. | Egetis Therapeutics AB: European Commission approves Egetis' Emcitate (tiratricol) as the first and only treatment for patients with MCT8 deficiency | 398 | GlobeNewswire (Europe) | Stockholm, Sweden, February 13, 2025. Egetis Therapeutics AB (publ) ("Egetis" or the "Company") (Nasdaq Stockholm: EGTX), today announced that the European Commission (EC) has approved Emcitate® (tiratricol)... ► Artikel lesen |
14 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| SANOFI | 83,07 | -0,04 % | BERNSTEIN RESEARCH stuft SANOFI auf 'Outperform' | NEW YORK (dpa-AFX Analyser) - Das US-Analysehaus Bernstein Research hat die Einstufung für Sanofi nach dem Auftritt des Finanzchefs auf einer Bernstein-Konferenz auf "Outperform" mit einem Kursziel... ► Artikel lesen | |
| GSK | 20,770 | -0,05 % | JPMORGAN stuft GSK auf 'Underweight' | NEW YORK (dpa-AFX Analyser) - Die US-Bank JPMorgan hat das Kursziel für GSK von 1500 auf 1700 Pence angehoben, aber die Einstufung auf "Underweight" belassen. Bei GSK erwartet Analyst Richard Vosser... ► Artikel lesen | |
| ASTRAZENECA | 153,10 | -1,38 % | JPMORGAN stuft ASTRAZENECA auf 'Positiv' | NEW YORK (dpa-AFX Analyser) - Die US-Bank JPMorgan hat das Kursziel für Astrazeneca von 14000 auf 16000 Pence angehoben und die Einstufung auf "Overweight" belassen. Analyst Richard Vosser setzte die... ► Artikel lesen | |
| TILRAY BRANDS | 10,200 | 0,00 % | Opening Bell: Eli Lilly, Broadcom, Planet Labs, Tilray, Citigroup, JPMorgan, Amazon, Nvidia | Die US-Börsen haben am Donnerstag uneinheitlich geschlossen. Der Dow Jones legte deutlich zu, markierte bei 48.756,34 Punkten ein neues Rekordhoch und beendete den Handel 1,34 Prozent höher. Der Nasdaq... ► Artikel lesen | |
| DERMAPHARM | 37,100 | +0,27 % | Dermapharm: Ausblick auf die weitere Kursentwicklung | ||
| QUANTUM BIOPHARMA | 8,200 | +3,14 % | Quantum BioPharma Ltd.: Quantum BioPharma Announces Closing of Private Placement & Provides Corporate Update | Toronto, Ontario--(Newsfile Corp. - December 10, 2025) - Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FSE: 0K91) ("Quantum BioPharma" or the "Company"), a biopharmaceutical company dedicated... ► Artikel lesen | |
| TONIX PHARMACEUTICALS | 16,700 | +1,21 % | Tonix Pharmaceuticals Holding Corp.: Tonix Pharmaceuticals Appoints Irina Ishak as General Counsel | ||
| CASSAVA SCIENCES | 2,611 | +4,44 % | Cassava Sciences, Inc.: Cassava Reports Q2 2025 Financials Results and Provides Business Update | Following positive preclinical data, simufilam development to advance with a clinical study expected to begin in H1 2026 for the potential treatment of TSC-related epilepsyRecent appointment of experienced... ► Artikel lesen | |
| OPKO HEALTH | 1,169 | -0,88 % | Here's Why You Should Retain OPKO Health Stock in Your Portfolio Now | ||
| SELLAS LIFE SCIENCES | 1,780 | +2,65 % | Sellas Life Sciences: Aktie legt nach vielversprechenden Studiendaten zu AML-Therapie zu | ||
| SOLIGENIX | 1,655 | +1,53 % | Soligenix, Inc.: Soligenix Inc. (NASDAQ: SNGX) Advancing Rare-Disease Therapies Positioned at Pivotal Crossroad | ||
| BETTERLIFE PHARMA | 0,025 | -10,71 % | BetterLife Pharma Inc.: BetterLife Pharma Announces Engagement with Shanghai-Based YAFO Capital | Vancouver, British Columbia--(Newsfile Corp. - December 11, 2025) - BetterLife Pharma Inc. (CSE: BETR) (OTCQB: BETRF) (FSE: NPAU) ("BetterLife" or the "Company"), an emerging biotech company focused... ► Artikel lesen | |
| THERIVA BIOLOGICS | 0,219 | -4,61 % | Theriva Biologics, Inc.: Theriva Biologics Reports Third Quarter 2025 Operational Highlights and Financial Results | - Expanded data for VCN-01 (zabilugene almadenorepvec) in metastatic pancreatic ductal adenocarcinoma (PDAC) from the VIRAGE Phase 2b trial presented at the European Society for Medical Oncology (ESMO)... ► Artikel lesen | |
| NOVABAY PHARMACEUTICALS | 2,810 | -2,09 % | NovaBay Pharmaceuticals, Inc. Regains Compliance with NYSE American Continued Listing Standards | EMERYVILLE, Calif., Oct. 20, 2025 (GLOBE NEWSWIRE) -- NovaBay Pharmaceuticals, Inc. (NYSE American: NBY) ("NovaBay" or the "Company") announces that it has regained compliance with the NYSE American's... ► Artikel lesen | |
| BAYER | 36,500 | +0,47 % | Bayer: Wochengewinner in KW 49 im DAX! |
EGETIS THERAPEUTICS AB gehört der Branche Pharma an. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 0,451 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu EGETIS THERAPEUTICS AB finden Sie auf Wallstreet Online.